Hélène Lelièvre
Domain Therapeutics (France)(FR)Sulzer (United Kingdom)(GB)
Publications by Year
Research Areas
CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Histone Deacetylase Inhibitors Research, Radiopharmaceutical Chemistry and Applications, Protein Degradation and Inhibitors
Most-Cited Works
- → The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression(2013)126 cited
- → Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm(2020)70 cited
- → Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome(2017)62 cited
- → Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia(2015)38 cited
- → Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome(2005)37 cited
- → Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts(2014)36 cited
- → Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome(2008)14 cited
- → Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia(2018)14 cited
- → Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies(2017)12 cited
- → Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy(2018)9 cited